Expert panel provides guidance for optimized design of early drug trials for Alzheimer s, related dementias
An expert panel convened by the Alzheimer s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) provides guidance on best practices for the design of early drug trials for Alzheimer s disease, frontotemporal degeneration (FTD), and other neurodegenerative dementias. Their guidance was published in the May 18, 2021 issue of
Neurology®, the medical journal of the American Academy of Neurology ( Value-Generating Exploratory Trials in Neurodegenerative Dementias ).
These efficiencies in clinical trials can help to achieve proof of concept more rapidly and at lower costs. The estimated cost of developing an Alzheimer s drug is eight times more than a cancer drug and takes nearly twice as long to develop. The panel, which comprised clinicians, researchers, and statisticians from academia, biotech, and pharmaceutical companies, as well as A